Business Context and Reporting Period
Company: Pacific Biosciences of California, Inc. (PACB)
Filing Type: Form 8-K (Current Report)
Date of Report: February 9, 2021
Event: Entry into a Material Definitive Agreement for the issuance and sale of convertible senior notes.
Key Financial Metrics and Transaction Details
This filing details a specific financing transaction rather than periodic financial performance metrics (revenue, profit, cash flow). The filing text does not provide current revenue, profit, or liquidity figures.
- Instrument: 1.50% Convertible Senior Notes due 2028.
- Aggregate Principal Amount: $900,000,000.
- Purchaser: SB Northstar LP.
- Interest Rate: 1.50% per annum, payable semi-annually in arrears starting August 15, 2021.
- Maturity Date: February 15, 2028.
- Initial Conversion Price: $43.50 per share (22.9885 shares per $1,000 principal).
- Redemption: Company may redeem on or after February 20, 2026, if the stock price exceeds 150% of the conversion price for 20 of 30 trading days.
Material Changes and Agreements
The primary material change is the execution of an Investment Agreement with SB Northstar LP. Key contractual obligations include:
- Standstill Obligations: The Purchaser is restricted from acquiring more than 19.99% of voting securities, initiating proxy contests, or influencing the Board for a period of three years from Closing (or until a change of control).
- Transfer Restrictions: The Purchaser cannot transfer the Notes or hedging positions for one year post-Closing, with limited exceptions for affiliates or margin calls.
- Fundamental Change: Holders may require repurchase at par plus accrued interest upon a change of control or delisting of the Company's stock.
Guidance, Outlook, and Risks
Outlook: The transaction is expected to close in approximately one week, subject to customary conditions. Proceeds are intended to strengthen the Company's balance sheet, though specific allocation of funds is not detailed in this text.
Risks and Contingencies:
- Dilution: Conversion of the Notes will result in the issuance of new common stock, subject to anti-dilution adjustments.
- Default: The Indenture includes customary events of default that could accelerate maturity.
- Market Conditions: Redemption rights are contingent on the Company's stock price performance relative to the conversion price.
Investor Verification Checklist
- Verify the final closing date of the $900 million transaction.
- Review the full text of the Indenture (Exhibit 4.1) for specific covenants and default triggers.
- Monitor the Company's stock price relative to the $43.50 conversion price to assess conversion likelihood.
- Confirm the use of proceeds in subsequent filings (e.g., 10-Q or 10-K) to understand capital allocation strategy.
- Check for any subsequent amendments to the Standstill or Transfer Restrictions.